Freya Bidco (EQT & ADIA) Acquires Dechra Pharmaceuticals plc
June 2, 2023
Freya Bidco Limited, an acquisition vehicle indirectly owned by EQT Private Equity and Luxinva S.A. (a wholly owned subsidiary of the Abu Dhabi Investment Authority), reached a recommended cash acquisition of UK‑listed Dechra Pharmaceuticals plc, valued at approximately GBP 4.459 billion (3,875 pence per share). The scheme was approved by the requisite majority of Dechra shareholders; EQT said it will support Dechra’s next phase of growth by investing in its veterinary pharmaceuticals pipeline and furthering global expansion.
- Buyers
- Freya Bidco Limited, EQT Private Equity, Luxinva S.A. (Abu Dhabi Investment Authority)
- Targets
- Dechra Pharmaceuticals plc
- Sellers
- Dechra shareholders
- Industry
- Pharmaceuticals
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Dechra Pharmaceuticals to Acquire Invetx
July 18, 2024
Biotechnology
Dechra Pharmaceuticals Limited has agreed to acquire Boston-based Invetx Inc., a developer of species-specific monoclonal antibody therapeutics for companion animals, for up to $520 million on a cash-free, debt-free basis, subject to customary approvals. The deal gives Dechra access to Invetx's pipeline and half-life extension platform to expand its specialty veterinary biologics capabilities.
-
Dechra Pharmaceuticals Acquires Med-Pharmex from DW Healthcare Partners
August 30, 2022
Veterinary
Dechra Pharmaceuticals PLC has completed the acquisition of Med-Pharmex Holdings, Inc. from DW Healthcare Partners. The deal brings a US-based, fully integrated veterinary pharmaceutical manufacturer (Med-Pharmex) into Dechra's global animal-health platform to strengthen its manufacturing capabilities and North American footprint.
-
Adare Pharma Solutions Acquires Frontida BioPharm
December 1, 2021
Pharmaceuticals
Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.
-
Swedencare AB (publ) Acquires Animal Pharmaceuticals Inc.
September 24, 2020
Veterinary
Swedencare AB (publ) acquired the operations of US-based Animal Pharmaceuticals Inc. for an initial purchase price of USD 15 million (approx. 131 million SEK) plus a potential earnout of up to USD 10 million; consideration includes cash and a directed new share issue. The deal (closed via newly established US subsidiary Animal Pharm Care USA, Inc.) adds a portfolio of supplements and topical veterinary products sold to ~8,500 US veterinary clinics and positions founder Jason Braun to lead the business and become a major Swedencare shareholder.
-
Eli Lilly Acquires Dermira for $1.1 Billion
January 10, 2020
Biotechnology
Eli Lilly agreed to acquire Dermira, Inc. in an all-cash transaction valued at approximately $1.1 billion ($18.75 per share). The deal adds Dermira's Phase 3 IL-13 antibody candidate lebrikizumab and marketed dermatology product QBREXZA to Lilly's immunology and dermatology portfolio and is expected to close in Q1 2020.
-
Veeda Clinical Research Acquires European CRO Heads
March 26, 2024
Healthcare Services
Veeda Clinical Research Limited has acquired Heads, a privately held European contract research organization (CRO) specializing in oncology clinical trials. The acquisition gives Veeda an expanded global footprint (Heads operates across ~25 locations) and integrated oncology clinical development capabilities, positioning Veeda as a full-service global CRO.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.